Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers at Oxford’s Nuffield Department of Surgical Sciences (NDS) and the Department of Physiology, Anatomy and Genetics (DPAG) have received several awards and accolades for their work on a novel software algorithm that analyses kidney stones.

Graph shows a comparison between two kidney stones using the software algorithm © Daniel Stevens
Graph shows a comparison between two kidney stones using the software algorithm

The new technology analyses the features of kidney stones on a CT scan and makes an assessment of the likelihood that they will fracture during lithotripsy treatment. A pilot study with 126 patients has been conducted and the team are now working on a larger study of 800 patients.

The project, which is led by Daniel Stevens (Cancer Research UK Clinical Research Training Fellow and DPhil candidate at DPAG) and Helen Cui (Urology Clinical Research Fellow) and supervised by Mr Ben Turney (Clinical Lecturer in Urology at NDS), has been attracting a lot of attention.

In March of this year, the team won ‘Best Presentation’ at the East Meets West Joint Meeting of East and West Midlands Urologists in Leicester, and were awarded 'Best Poster in Session' and highlighted as ‘exciting new technology’ at the European Association of Urology 2016 Annual Congress in Munich. Also, Daniel was awarded the Malcolm Coptcoat Spring Prize by the Royal Society of Medicine for his work on the project.

In addition, last year the team were highlighted as a 'Flagship Poster' at the Challenges in Endourology International Meeting in Paris.

Commenting on the project’s success to date, Daniel said: ‘Lithotripsy only works two-thirds of the time which means patients undergo unnecessary treatments and the NHS does not make best use of its resources. The software we have developed gives additional information on top of the predictive clinical factors we already know about. We now hope that the promising preliminary results we have seen will be confirmed in our larger study. We are delighted that this work has been recognised and ultimately hope that we can benefit both patients and the NHS by using our algorithm in the clinic as soon as possible.’

Similar stories

New reporting guidelines developed to improve AI in healthcare settings

New reporting guidelines, jointly published in Nature Medicine and the BMJ by Oxford researchers, will ensure that early studies on using Artificial Intelligence (AI) to treat real patients will give researchers the information needed to develop AI systems safely and effectively.

Results of the REF 2021: congratulations and thank you

Today, the UK funding bodies have published the results of the UK’s most recent national research assessment exercise, the Research Excellence Framework (REF) 2021.

Another successful year for SITU NDS

The Surgical Intervention Trials Unit in the Nuffield Department of Surgical Sciences (SITU NDS) has had another successful year, now running ten randomised controlled trials across surgical specialties and securing a total of £32 million in current peer-reviewed grants.

Blog posts

Lights, camera, action! My journey into video production

Dr Hannah McGivern provides a 'behind-the-scenes' account of her experience producing the video 'Journey of a QUOD Sample: Donating to Transplant Research', supported by the funds from the University of Oxford Public Engagement with Research (PER) Seed Fund.

Mentoring in practice

NDS has launched a new, interdepartmental mentoring scheme called RECOGNISE. In this podcast, Gemma Horbatowski (HR Advisor) interviews Monica Dolton (Programme Manager and Research Project Manager) about her experiences of mentor-mentee relationships.

Wrap up of 2021

After a brilliant year of hard work and dedication, the SITU team has done some reflection on 2021, focusing on key events, trial progression, and more. Read on to discover how the year 2021 went for the SITU team...